{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:56:58Z","timestamp":1781614618573,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoxia is a key feature of the tumor microenvironment, and can promote tumor progression. FOXD1 has been found to be involved in several types of cancer; however, its role in mediating cancer cell growth under hypoxia conditions is unclear. In this study, we aimed to test the effect of FOXD1 on prostate cancer cell growth in response to hypoxia. Our results showed that FOXD1 expression was upregulated in prostate cancer. Under normoxia conditions, FOXD1 knockdown inhibited prostate cancer cell viability and colony formation, while FOXD1 overexpression exhibited the opposite effects. Hypoxia exposure increased the expression of FOXD1 in prostate cancer. FOXD1 knockdown inhibited hypoxia-induced increase in cell viability and colony formation ability, whereas FOXD1 overexpression showed the opposite effects. In addition, FOXD1 knockdown inhibited hypoxia-induced increase in lactate production, glucose consumption, and the expression levels of HK-2 and LDHA. Moreover, inhibition of glycolysis by 2-deoxyglucose reversed the effect of FOXD1 overexpression on hypoxia-induced prostate cancer cell growth. These results indicated that hypoxia-induced FOXD1 expression accelerated glycolysis, ultimately promoting prostate cancer cell growth.<\/jats:p>","DOI":"10.1186\/s12896-025-01061-6","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T12:07:51Z","timestamp":1762776471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FOXD1, a hypoxia-related gene, accelerates prostate cancer cell growth by increasing glycolysis under hypoxia conditions"],"prefix":"10.1186","volume":"25","author":[{"given":"Jing","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"17","key":"1061_CR1","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: Genetics, Diagnosis, treatment Options, and alternative approaches. Molecules. 2022;27(17):5730.","journal-title":"Molecules"},{"issue":"3","key":"1061_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354\u201373.","journal-title":"Endocr Rev"},{"issue":"6","key":"1061_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"7","key":"1061_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrurol.2013.110","volume":"10","author":"L Marignol","year":"2013","unstructured":"Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, Notch signalling, and prostate cancer. Nat Rev Urol. 2013;10(7):405\u201313.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"1061_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy Javanmard S, Taherian M, Ahmadlou M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62.","journal-title":"Cancer Cell Int"},{"issue":"49","key":"1061_CR6","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41388-023-02869-2","volume":"42","author":"P Fan","year":"2023","unstructured":"Fan P, Zhang N, Candi E, Agostini M, Piacentini M, Centre TOR, Shi Y, Huang Y, Melino G. Alleviating hypoxia to improve cancer immunotherapy. Oncogene. 2023;42(49):3591\u2013604.","journal-title":"Oncogene"},{"issue":"7","key":"1061_CR7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cells10071715","volume":"10","author":"MH Bao","year":"2021","unstructured":"Bao MH, Wong CC, Hypoxia. Metabolic Reprogramming, and drug resistance in liver cancer. Cells. 2021;10(7):1715.","journal-title":"Cells"},{"issue":"11","key":"1061_CR8","doi-asserted-by":"publisher","first-page":"5703","DOI":"10.3390\/ijms22115703","volume":"22","author":"V Infantino","year":"2021","unstructured":"Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci. 2021;22(11):5703.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1061_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","volume":"18","author":"X Jing","year":"2019","unstructured":"Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.","journal-title":"Mol Cancer"},{"issue":"4","key":"1061_CR10","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1007\/s11033-023-08251-5","volume":"50","author":"OAA Mohamed","year":"2023","unstructured":"Mohamed OAA, Tesen HS, Hany M, Sherif A, Abdelwahab MM, Elnaggar MH. The role of hypoxia on prostate cancer progression and metastasis. Mol Biol Rep. 2023;50(4):3873\u201384.","journal-title":"Mol Biol Rep"},{"issue":"1115","key":"1061_CR11","doi-asserted-by":"publisher","first-page":"20200087","DOI":"10.1259\/bjr.20200087","volume":"93","author":"J Ashton","year":"2020","unstructured":"Ashton J, Bristow R. Bad neighbours: hypoxia and genomic instability in prostate cancer. Br J Radiol. 2020;93(1115):20200087.","journal-title":"Br J Radiol"},{"issue":"8","key":"1061_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00109-018-1665-2","volume":"96","author":"P Quintero-Ronderos","year":"2018","unstructured":"Quintero-Ronderos P, Laissue P. The multisystemic functions of FOXD1 in development and disease. J Mol Med (Berl). 2018;96(8):725\u201339.","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"1061_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s10020-019-0104-3","volume":"25","author":"P Quintero-Ronderos","year":"2019","unstructured":"Quintero-Ronderos P, Jimenez KM, Esteban-Perez C, Ojeda DA, Bello S, Fonseca DJ, Coronel MA, Moreno-Ortiz H, Sierra-Diaz DC, Lucena E, et al. FOXD1 mutations are related to repeated implantation failure, intra-uterine growth restriction and preeclampsia. Mol Med. 2019;25(1):37.","journal-title":"Mol Med"},{"key":"1061_CR14","doi-asserted-by":"crossref","unstructured":"Gomez IG, Duffield JS. The FOXD1 lineage of kidney perivascular cells and myofibroblasts: functions and responses to injury. Kidney Int Suppl (2011). 2014;4(1):26\u201333.","DOI":"10.1038\/kisup.2014.6"},{"key":"1061_CR15","doi-asserted-by":"publisher","first-page":"150632","DOI":"10.1016\/j.bbrc.2024.150632","volume":"734","author":"K Yamagata","year":"2024","unstructured":"Yamagata K, Takasuga S, Tatematsu M, Fuchimukai A, Yamada T, Mizuno M, Morii M, Ebihara T. FoxD1 expression identifies a distinct subset of hepatic stellate cells involved in liver fibrosis. Biochem Biophys Res Commun. 2024;734:150632.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1061_CR16","doi-asserted-by":"publisher","first-page":"FSO901","DOI":"10.2144\/fsoa-2023-0085","volume":"10","author":"X Liu","year":"2024","unstructured":"Liu X, Min S, Zhang Q, Liu Y, Zou Z, Wang N, Zhou B. Prognostic and clinicopathological significance of FOXD1 in various cancers: a meta and bioinformation analysis. Future Sci OA. 2024;10(1):FSO901.","journal-title":"Future Sci OA"},{"issue":"5","key":"1061_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3892\/etm.2023.12212","volume":"26","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhang L, Liu T, Liang E. LMNB1 targets FOXD1 to promote progression of prostate cancer. Exp Ther Med. 2023;26(5):513.","journal-title":"Exp Ther Med"},{"key":"1061_CR18","doi-asserted-by":"publisher","first-page":"146680","DOI":"10.1016\/j.gene.2022.146680","volume":"836","author":"C Donmez","year":"2022","unstructured":"Donmez C, Konac E. Silencing effects of FOXD1 inhibit metastatic potentials of the PCa via N-cadherin - Wnt\/beta-catenin crosstalk. Gene. 2022;836:146680.","journal-title":"Gene"},{"issue":"W1","key":"1061_CR19","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98\u2013102.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1061_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/pcan.2011.51","volume":"15","author":"SM Manohar","year":"2012","unstructured":"Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1alpha and induces G2\/M arrest under hypoxia in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012;15(1):15\u201327.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"1061_CR21","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3892\/ijo.2012.1610","volume":"41","author":"LJ Xiao","year":"2012","unstructured":"Xiao LJ, Chen YY, Lin P, Zou HF, Lin F, Zhao LN, Li D, Guo L, Tang JB, Zheng XL, et al. Hypoxia increases CX3CR1 expression via HIF-1 and NF\u2013kappaB in androgen-independent prostate cancer cells. Int J Oncol. 2012;41(5):1827\u201336.","journal-title":"Int J Oncol"},{"issue":"11","key":"1061_CR22","doi-asserted-by":"publisher","first-page":"e12918","DOI":"10.1111\/cpr.12918","volume":"53","author":"L Xia","year":"2020","unstructured":"Xia L, Sun J, Xie S, Chi C, Zhu Y, Pan J, Dong B, Huang Y, Xia W, Sha J, et al. PRKAR2B-HIF-1alpha loop promotes aerobic Glycolysis and tumour growth in prostate cancer. Cell Prolif. 2020;53(11):e12918.","journal-title":"Cell Prolif"},{"issue":"4","key":"1061_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/path.4413","volume":"234","author":"S Yu","year":"2014","unstructured":"Yu S, Xu Z, Zou C, Wu D, Wang Y, Yao X, Ng CF, Chan FL. Ion channel TRPM8 promotes hypoxic growth of prostate cancer cells via an O2 -independent and RACK1-mediated mechanism of HIF-1alpha stabilization. J Pathol. 2014;234(4):514\u201325.","journal-title":"J Pathol"},{"issue":"1","key":"1061_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/path.4329","volume":"233","author":"C Zou","year":"2014","unstructured":"Zou C, Yu S, Xu Z, Wu D, Ng CF, Yao X, Yew DT, Vanacker JM, Chan FL. ERRalpha augments HIF-1 signalling by directly interacting with HIF-1alpha in normoxic and hypoxic prostate cancer cells. J Pathol. 2014;233(1):61\u201373.","journal-title":"J Pathol"},{"issue":"11","key":"1061_CR25","doi-asserted-by":"publisher","first-page":"8546","DOI":"10.1002\/jcp.29698","volume":"235","author":"Y Fan","year":"2020","unstructured":"Fan Y, Ou L, Fan J, Li L, Wang X, Niu L, Wu X, Luo C. PLCepsilon regulates metabolism and metastasis signaling via HIF-1alpha\/MEK\/ERK pathway in prostate cancer. J Cell Physiol. 2020;235(11):8546\u201357.","journal-title":"J Cell Physiol"},{"key":"1061_CR26","doi-asserted-by":"publisher","first-page":"1156111","DOI":"10.3389\/fonc.2023.1156111","volume":"13","author":"K Kumegawa","year":"2023","unstructured":"Kumegawa K, Yang L, Miyata K, Maruyama R. FOXD1 is associated with poor outcome and maintains tumor-promoting enhancer-gene programs in basal-like breast cancer. Front Oncol. 2023;13:1156111.","journal-title":"Front Oncol"},{"issue":"9","key":"1061_CR27","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41419-022-05213-w","volume":"13","author":"K Cai","year":"2022","unstructured":"Cai K, Chen S, Zhu C, Li L, Yu C, He Z, Sun C. FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic Glycolysis. Cell Death Dis. 2022;13(9):765.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1061_CR28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1878-0261.12728","volume":"15","author":"Q Wu","year":"2021","unstructured":"Wu Q, Ma J, Wei J, Meng W, Wang Y, Shi M. FOXD1-AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K\/AKT\/mTOR pathway. Mol Oncol. 2021;15(1):299\u2013316.","journal-title":"Mol Oncol"},{"issue":"1","key":"1061_CR29","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/or.2023.8571","volume":"50","author":"WQ Feng","year":"2023","unstructured":"Feng WQ, Zhang YC, Gao H, Li WC, Miao YM, Xu ZF, Xu ZQ, Zhao JK, Zheng MH, Zong YP, et al. FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through beta\u2013catenin nuclear localization. Oncol Rep. 2023;50(1):134.","journal-title":"Oncol Rep"},{"issue":"9","key":"1061_CR30","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.3390\/cancers12092690","volume":"12","author":"CH Lin","year":"2020","unstructured":"Lin CH, Lee HH, Chang WM, Lee FP, Chen LC, Lu LS, Lin YF. FOXD1 repression potentiates radiation effectiveness by downregulating G3BP2 expression and promoting the activation of TXNIP-Related pathways in oral cancer. Cancers (Basel). 2020;12(9):2690.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1061_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.biocel.2006.07.001","volume":"39","author":"M Valko","year":"2007","unstructured":"Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44\u201384.","journal-title":"Int J Biochem Cell Biol"},{"issue":"22","key":"1061_CR32","doi-asserted-by":"publisher","first-page":"6959","DOI":"10.1111\/febs.16115","volume":"289","author":"MP Mori","year":"2022","unstructured":"Mori MP, Penjweini R, Knutson JR, Wang PY, Hwang PM. Mitochondria and oxygen homeostasis. FEBS J. 2022;289(22):6959\u201368.","journal-title":"FEBS J"},{"issue":"1","key":"1061_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","volume":"7","author":"Z Luo","year":"2022","unstructured":"Luo Z, Tian M, Yang G, Tan Q, Chen Y, Li G, Zhang Q, Li Y, Wan P, Wu J. Hypoxia signaling in human health and diseases: implications and prospects for therapeutics. Signal Transduct Target Ther. 2022;7(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"1061_CR34","doi-asserted-by":"publisher","first-page":"e159839","DOI":"10.1172\/JCI159839","volume":"132","author":"EE Wicks","year":"2022","unstructured":"Wicks EE, Semenza GL. Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest. 2022;132(11):e159839.","journal-title":"J Clin Invest"},{"key":"1061_CR35","doi-asserted-by":"publisher","first-page":"153303382110363","DOI":"10.1177\/15330338211036304","volume":"20","author":"Y Li","year":"2021","unstructured":"Li Y, Zhao L, Li XF. Hypoxia and the tumor microenvironment. Technol Cancer Res Treat. 2021;20:15330338211036304.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"1061_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40336-017-0231-1","volume":"5","author":"A Challapalli","year":"2017","unstructured":"Challapalli A, Carroll L, Aboagye EO. Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging. 2017;5(3):225\u201353.","journal-title":"Clin Transl Imaging"},{"issue":"1","key":"1061_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2021.10.004","volume":"8","author":"SJ Cowman","year":"2022","unstructured":"Cowman SJ, Koh MY. Revisiting the HIF switch in the tumor and its immune microenvironment. Trends Cancer. 2022;8(1):28\u201342.","journal-title":"Trends Cancer"},{"issue":"9","key":"1061_CR38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/cells8091083","volume":"8","author":"MZ Noman","year":"2019","unstructured":"Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G, Janji B. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges. Cells. 2019;8(9):1083.","journal-title":"Cells"},{"issue":"1","key":"1061_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, Adam V. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1061_CR40","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1080\/14728222.2023.2248381","volume":"27","author":"Y Zohar","year":"2023","unstructured":"Zohar Y, Mabjeesh NJ. Targeting HIF-1 for prostate cancer: a synthesis of preclinical evidence. Expert Opin Ther Targets. 2023;27(8):715\u201331.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"1061_CR41","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/cells12050798","volume":"12","author":"A Yfantis","year":"2023","unstructured":"Yfantis A, Mylonis I, Chachami G, Nikolaidis M, Amoutzias GD, Paraskeva E, Simos G. Transcriptional response to hypoxia: the role of HIF-1-associated co-regulators. Cells. 2023;12(5):798.","journal-title":"Cells"},{"key":"1061_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/1471-2407-12-463","volume":"12","author":"H Stegeman","year":"2012","unstructured":"Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Gr\u00e9nman R, Span PN, Bussink J. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer. 2012;12:463.","journal-title":"BMC Cancer"},{"issue":"4","key":"1061_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/10799893.2020.1808679","volume":"41","author":"X Zuo","year":"2021","unstructured":"Zuo X, Li L, Sun L. Plantamajoside inhibits hypoxia-induced migration and invasion of human cervical cancer cells through the NF-\u03baB and PI3K\/akt pathways. J Recept Signal Transduct Res. 2021;41(4):339\u201348.","journal-title":"J Recept Signal Transduct Res"},{"issue":"3","key":"1061_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41419-019-1431-6","volume":"10","author":"C Chen","year":"2019","unstructured":"Chen C, Xu ZQ, Zong YP, Ou BC, Shen XH, Feng H, Zheng MH, Zhao JK, Lu AG. CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT\/NF-\u03baB pathway in colorectal cancer. Cell Death Dis. 2019;10(3):178.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1061_CR45","doi-asserted-by":"publisher","first-page":"a040535","DOI":"10.1101\/cshperspect.a040535","volume":"13","author":"NS Chandel","year":"2021","unstructured":"Chandel NS, Glycolysis. Cold Spring Harb Perspect Biol. 2021;13(5):a040535.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"Pt 3","key":"1061_CR46","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.semcancer.2022.09.007","volume":"86","author":"S Paul","year":"2022","unstructured":"Paul S, Ghosh S, Kumar S. Tumor glycolysis, an essential sweet tooth of tumor cells. Semin Cancer Biol. 2022;86(Pt 3):1216\u201330.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"1061_CR47","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41556-019-0299-0","volume":"21","author":"F Chen","year":"2019","unstructured":"Chen F, Chen J, Yang L, Liu J, Zhang X, Zhang Y, Tu Q, Yin D, Lin D, Wong PP, et al. Extracellular vesicle-packaged HIF-1alpha-stabilizing LncRNA from tumour-associated macrophages regulates aerobic Glycolysis of breast cancer cells. Nat Cell Biol. 2019;21(4):498\u2013510.","journal-title":"Nat Cell Biol"},{"issue":"2 Pt C","key":"1061_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.molimm.2015.07.034","volume":"68","author":"RP Donnelly","year":"2015","unstructured":"Donnelly RP, Finlay DK. Glucose, Glycolysis and lymphocyte responses. Mol Immunol. 2015;68(2 Pt C):513\u20139.","journal-title":"Mol Immunol"},{"key":"1061_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fcell.2018.00122","volume":"6","author":"RJ Salmond","year":"2018","unstructured":"Salmond RJ. mTOR regulation of glycolytic metabolism in T cells. Front Cell Dev Biol. 2018;6:122.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1061_CR50","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341.","journal-title":"Cell"},{"issue":"9","key":"1061_CR51","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109(9):3812\u20139.","journal-title":"Blood"},{"issue":"4","key":"1061_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.15586\/qas.v14i4.1141","volume":"14","author":"M Wang","year":"2022","unstructured":"Wang M, Dai L, Yan W, Chen Y, Wang Y. Brusatol inhibits the growth of prostate cancer cells and reduces HIF-1\u03b1\/VEGF expression and Glycolysis under hypoxia. Qual Assur Saf Crops Foods. 2022;14(4):13\u201322.","journal-title":"Qual Assur Saf Crops Foods"},{"issue":"1","key":"1061_CR53","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.repbio.2024.100969","volume":"25","author":"H Gao","year":"2025","unstructured":"Gao H, Wang J, Liu J, Wang H, Wang T, Li S, Niu L, Wei Y. FOXD1 activates KIFC1 to modulate aerobic Glycolysis and reinforce cisplatin resistance of breast cancer. Reprod Biol. 2025;25(1):100969.","journal-title":"Reprod Biol"},{"issue":"1","key":"1061_CR54","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s12672-025-03473-4","volume":"16","author":"Q Yuan","year":"2025","unstructured":"Yuan Q, Liu H, Song C, Tian Y, Hassan W, Shabbir R, Wenjuan C, Han L. Prevalence of GLUT1 overexpression in human cancers a systematic review and meta analysis. Discov Oncol. 2025;16(1):1761.","journal-title":"Discov Oncol"},{"issue":"3","key":"1061_CR55","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3390\/diagnostics12030676","volume":"12","author":"JM Ryniawec","year":"2022","unstructured":"Ryniawec JM, Coope MR, Loertscher E, Bageerathan V, de Oliveira Pessoa D, Warfel NA, Cress AE, Padi M, Rogers GC. GLUT3\/SLC2A3 is an endogenous marker of hypoxia in prostate cancer cell lines and patient-derived xenograft tumors. Diagnostics. 2022;12(3):676.","journal-title":"Diagnostics"},{"issue":"6","key":"1061_CR56","first-page":"1561","volume":"20","author":"GD Stewart","year":"2008","unstructured":"Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, Habib FK. Analysis of hypoxia-associated gene expression in prostate cancer: Lysyl oxidase and glucose transporter-1 expression correlate with Gleason score. Oncol Rep. 2008;20(6):1561\u20137.","journal-title":"Oncol Rep"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-025-01061-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01061-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:18:08Z","timestamp":1781612288000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12896-025-01061-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1061"],"URL":"https:\/\/doi.org\/10.1186\/s12896-025-01061-6","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}